Sexual Health
Sexual-health treatment pathways depend on clinician review, contraindication screening, and state availability.
Prescription required
Safety screening is required
Not all treatments are available in all states
Clinician-guided treatment pathways
Options in this category require screening for contraindications, medication interactions, and indication-specific fit. Compounded products are not FDA-approved and are not presented as interchangeable with generic or brand drugs.
Treatment pathways in this category are reviewed case by case. Contact support if you would like to discuss current availability with the care team.
How these options are considered
A clinician reviews symptoms, relevant medical history, and medication use before determining whether any prescription path is appropriate. Product selection and availability vary by patient and state.
Prescription and safety screening required
- Compounded PDE5 products are not FDA-approved and should not be presented as equivalent to FDA-approved generic or brand drugs.
- PDE5 inhibitors are contraindicated with nitrates and require clinician review of cardiovascular history and medication use.
- Bremelanotide has a narrower FDA-approved indication than the category as a whole and should be evaluated case by case.